Home › NCT05564494
Surgical Treatment of Recurrent Shoulder Dislocations
The Arthroscopic Treatment of Anterior Shoulder Instability (ATRASI): A Pilot Multicentre Randomized Controlled Trial
Who can join
Ages 16 to 40 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Recurrent anterior glenohumeral dislocation (two or more incidents) * Presence of glenoid and/or humerus bone loss on imaging (x Ray, CT or MRI) Exclusion Criteria: * Uncontrolled diabetes (Hgb A1C \>7%) * Prior surgery of affected shoulder * Pregnancy * Multidirectional instability * Posterior instability * Paralysis of the shoulder * Cancer * Severe systemic illness * Presence of massive rotator cuff tear * Patients that present with \< 10% or \> 25% bone loss under preoperative imaging. * Generalized laxity (\>5/9 Beighton Score)
About the study
This is a pilot multi-centre, double blinded randomized controlled trial. The primary outcome of this pilot trial will be feasibility. Prior to conducting a large definitive trial, the investigators will conduct this pilot trial comparing arthroscopic Bankart repair with arthroscopic anatomic glenoid reconstruction (AAGR), evaluating recurrent dislocation rates and functional outcomes over a 24-month period. The feasibility objectives are: (1) to evaluate the investigators ability to recruit patients across multiple sites and (2) to assess study protocol adherence and ability to follow patients to 24 months. Clinical objectives for the pilot trial are exploratory only. The investigators wish to gather means and standard deviations for clinical outcomes to power their future definitive trial. The objectives of the definitive trial will include a comparison of patient-reported outcomes at the two-year post-operative time point, differences in recurrence rates, complication rates, functional shoulder assessments, and return to work/sport.
What is being tested
- Bankart Repair (procedure)
- Anatomic Glenoid Reconstruction (procedure)
Sponsor: Nova Scotia Health Authority · Participants: 200 · Started: Apr 25, 2023
Contact the study team
- Matt Miller, PhD · Phone: 9024737626
Official record on ClinicalTrials.gov — NCT05564494
Locations in the U.S.
| New York | NYU Langone Health, New York |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.